Currently, the immunohistochemical assessment of PD-L1 expression level on formalin-fixed paraffin-embedded (FFPE) specimens is the only test employed in the clinic to guide the use of ICBs, and is an approved companion diagnostic for NSCLC patients considered for pembrolizumab treatment [19, 20]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.